MacroGenics, Inc. to Pour $70 Million Into Two Cancer Drugs  
9/27/2013 8:43:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MacroGenics Inc. plans to fuel development of two cancer drug candidates with $70 million from the proceeds of its upcoming initial public offering and other funding sources, the Rockville biotech said in an updated IPO filing. The funds — a combination of upcoming payments from big pharma collaborations, IPO winnings and cash stockpiles — will go toward pushing Margetuximab (A.K.A. MGAH22) and MGA271 through the clinic. Margetuximab, a monocolonal antibody, is in the midst of a Phase 2a trial for metastatic breast cancer and is slated to enter a Phase 3 trial for gastroesophageal cancer in the latter half of next year.

Help employers find you! Check out all the jobs and post your resume.